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Abstract
Bisphosphonates (BPs) are characterized by a PCP backbone structure and two phosphonic acid groups bonded to the same carbon,
and are established as osteoclast-mediated bone resorption inhibitors. The nature of the groups attached to the central carbon atom are
responsible in determining the potency of bisphosphonates as anti-resorption drugs. However, it is not yet clear the exact relationship
between their molecular structure and pharmacologic activities. In this study, molecular geometries of pamidronate, alendronate and
neridronate, differing only in the length of the aliphatic chains, were predicted by molecular mechanics and their interactions with
hydroxyapatite, the main bone mineral component, were examined. We report the synthesis and radiochemical characterization of 153Sm
complexes with pamidronate, alendronate and neridronate. Hydroxyapatite binding and biodistribution studies of these complexes have
shown a good correlation with the theoretical molecular modeling interaction studies. So, it is possible to conclude that computational
chemistry techniques are a good approach to evaluate specific interactions and may play a relevant role in determining the relative ability
of BPs to mineral bone, and open new perspectives to the design of new BPs with increased pharmacological activity. These techniques
could be extended to BPs as ligands to carrier radioactive metals, aiming for new bone therapeutic radiopharmaceuticals. © 2002 Elsevier
Science Inc. All rights reserved.
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1. Introduction
Inorganic pyrophosphate, a naturally occurring poly-
phosphate and a known by-product of many biosynthetic
reactions in the body, prevent calcification of soft tissues
and regulates bone mineralization. Like pyrophosphate,
bisphosphonates (BPs) have high affinity for bone mineral
and were found to prevent calcification both in vitro and in
vivo, and to inhibit the dissolution of hydroxyapatite crys-
tals [9]. BPs are synthetic analogous of pyrophosphate in
which the oxygen bridge has been replaced by a carbon
atom with two attached side chains and are established as
osteoclast-mediated bone resorption inhibitors. Some com-
pounds exhibit short side chains, such as clodronate and
etidronate; others have aliphatic chains of different lengths
bearing terminal amino groups (pamidronate, alendronate,
and neridronate) or substituted amino groups (olpadronate
and ibandronate). Among the last generation of BPs with
cyclic side chains, zoledronate with a nitrogen atom in an
imidazole ring, is the most potent bisphosphonate described
so far to inhibit bone resorption (Table 1). BPs, became the
treatment of choice for a variety of bone diseases in which
excessive osteoclast activity is an important pathological
feature, including Paget’s disease, metastatic and osteolytic
bone disease, and hypercalcemia of malignancy [8,28,29].
BPs are also used as ligands to coordinate technetium-99m
for bone scanning imaging [7] as methylene bisphosphonate
(MDP), hydroxyethylene bisphosphonate (HEDP) and hy-
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droxymethylene bisphosphonate (HMDP) or to coordinate
beta-emitter radionuclides (as samarium-153 and rhenium-
186) for bone pain palliation [17,22].
In BPs, the groups attached to the central carbon atom
determine their potency as anti-resorption drugs, thought it
is not yet clear the precise relationship between their mo-
lecular structure and pharmacologic activity [8]. In order to
shade light on the relationship between BPs molecular
structure and hydroxyapatite—Ca10(PO4)6(OH)2—the main
bone mineral component, we have carried out the following
studies:
Y a molecular modeling analysis, by molecular mechan-
ics (MM), of the molecular structures of pamidronate,
alendronate and neridronate—BPs differing only in
the length of their aliphatic chains—and of their in-
teraction with hydroxyapatite;
Y the synthesis and chemical characterization of pam-
idronate, alendronate and neridronate;
Y the synthesis and radiochemical characterization of
153Sm complexes of the above BPs;
Y in vitro hydroxyapatite binding and in vivo mice stud-
ies with the 153Sm-BPs complexes;
Y establishment of a correlation between the computa-
tional studies and the in vitro and in vivo results.
1.1. Mechanism of action of bisphosphonates
In spite of many valuable contributions, the exact mo-
lecular mechanism by which BPs inhibit bone resorption, is
not yet completely understood. Initially, BPs were supposed
to prevent calcification by a strict physicochemical mecha-
nism after adsorption to bone surfaces, but gradually be-
come clear that cellular effects must be involved. Several
authors suggest that the P-C-P moiety provides BPs with the
ability to bind avidly to bone mineral in vivo and the
anti-resorptive potency is critically dependent upon the
structure of the side chains attached to the geminal carbon
of the P-C-P moiety, and that the mechanism of action
involves specific stereo interactions [28]. As osteoclasts are
highly endocytic, BPs present in the resorption space may
be internalized by endocytosis, and thereby affect their
intracellular metabolism and induce apoptosis [29]. The
uptake of BPs by osteoclasts in vivo has been confirmed
using radiolabeled alendronate [21], which was internalized
into intracellular vacuoles, and other subcellular compart-
ments such as the cytoplasm, mitochondriae, and nuclei [28]
and by the current used in nuclear medicine practice, MDP
and HMDP labeled with Tc-99m for bone metastases im-
aging and Re-186/188 for bone palliation in patients with
metastatic involvement [22].
For BPs intervenction at cellular level they should be
presented at the osteoclast microenvironmental or resorp-
tion space, but it is not yet clear in which way their binding
to the bone mineral matrix—hydroxyapatite—-could affect
the distinct potencies of the different BPs. They also shorten
the life span of osteoclasts by inducing their programmed
cell dead (apoptosis) and their inhibitory effects also may be
mediated by other cells of the osteolineage or the macro-
phage family [11]. Recent in vitro studies indicate that BPs
also inhibit proliferation, reduce viability and induce apo-
ptosis in several human tumor cell lines. In addition, BPs
reduce the invasion of tumors cells through extracellular
matrix and impar the binding of tumor cells to bone in vitro.
BPs may have the potential to exert direct antitumor effects
in vivo, particularly in bone metastases where the local
concentration is elevated by the enhanced osteoclastic re-
sorption of BP-loaded bone [12]. The molecular mecha-
nisms by which tumor cells metastasize to bone are likely to
involve invasion, cell adhesion to bone, and release of
soluble mediators from tumor cells that stimulate osteoclast-
mediated bone resorption. According to Boissier et al.,
2000, [3], BPs pretreatment of breast and prostate carci-
noma cells inhibited tumor cell invasion in a dose-depen-
dent manner, and the order of potency of the BPs under
study follows the same order of antiresorptive potency (see
Table 1). Also, Fromigue et al., 2000, [11] reported that
clodronate, pamidronate, ibandronate and zoledronate can
inhibit breast cancer cell growth, namely MCF-7, T47D,
and MDA.MB.231 cell lines by inducing apoptosis or pri-
mary necrosis depending on the cell type and the BPs
concentration. The relative percentages of viable, apoptotic,
and necrotic cells to the total number of cells scored, fol-
lows also the relative order of antiresorptive potency, i.e.
zoledronate  ibandronate  pamidronate  clodronate.
So, BPs as antiresorptive agents or as cells growth inhibitors
follow identical relative order of potencies. From preclinical
studies with zoledronic acid and other BPs Mundy et al.,
2001, [24], conclude that bisphosphonate-associated tumor
reduction in bone is most likely mediated by osteoclast
inhibition or is related to high local concentration of BPs in
the bone compartment. It is interesting to note that BPs
inhibit tumor cells invasion in a dose-dependent manner,
and that apoptosis and necrosis of breast cancer cells are
depending of BPs concentration. If biologic effects are de-
pending of BPs concentration, it could mean that their
affinity to the bone matrix plays a fundamental role. So, it is
possible to admit that two conjugate effects—hydroxyapa-
Table 1
First and second bisphosphonates generation and their antiresorptive
potency in acute in vivo models
Bisphosphonate R1 R2 Potency*
Clodronate Cl Cl 10x
Etidronate OH CH3 1x
Pamidronate OH (CH2)2 NH2 100x
Alendronate OH (CH2)3 NH2 100–1000x
Neridronate OH (CH2)5 NH2 100x
Olpadronate OH (CH2)2 N(CH3)2 100–1000x
Ibandronate OH (CH2)2 N(CH3) (CH2)4 CH3 1000–10,000x
Risedronate OH CH2-3-pyridine 1000–10,000x
Zoledronate OH CH2-imidazole 10,000x
* From reference 8
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tite BPs binding and cellular interactions—would occur.
These two possible conjugate effects are supported by the
work of Shakespeare W. et al., 2000, [31], in which a
nonpeptide inhibitor (AP22408) with a bisphosphonate moi-
ety demonstrates a remarkably hydroxyapatite affinity, and
is the tighest binding inhibitor for Src SH2 (targeted dis-
ruption of the Src gene in mice has revealed a critical role
of Src in the osteoclats function) and shows in vitro antire-
sorptive properties in an osteoclast-mediated cellular assay
and in vivo TPTX model of parathyroid hormone-induced
bone resorption. Two negative controls, (a bone-targeted
analog that does not bind to Src SH2 and a nonbone-
targeted analog that has high affinity to bind Src SH2) in an
rabbit osteoclast resorption assay validate the AP22408 bi-
ological properties. It seems that both, bone-targeted via
hydroxyapatite binding and Src SH2 binding are essential.
Then, two mechanims could be outlined:
(i) BPs will bind to the bone mineral matrix and the
inhibition resorption will be the result of their inter-
action with cell(s) from the intracellular environ-
ment,
(ii) BPs will bind to the mineral matrix and it will
induces morphologic changes that lead to dimin-
ished crystal growth and may prevent the adhesion
of cells from extracelular environment.
These fact justifies the interest to structurally character-
ize the different BPs, since the peculiarities of their substi-
tuted groups shall correlate with their relative potencies as
powerful inhibitors of the osteoclast activity and as potential
inhibitors of specific cells growth.
1.2. Technetium, rhenium and lanthanide bisphosphonates
complexes
The exact molecular structure of technetium, rhenium
and lanthanide bisphosphonates complexes are not known.
The tendency of bisphosphonates as ligands, to form poly-
meric metal complexes complicates their isolation and char-
acterization. In general, the experimental characterization of
the molecular structure of technetium compounds is only
possible using the carrier radionuclide Tc-99 and, depend-
ing on the reaction conditions (e.g. pH, metal concentration,
presence or absence of oxygen, type of reducing agent), the
reduced technetium center exist in a variety of oxidation
states, mixed metal complexes, uncommon coordination
numbers, and hydrolyzed, colloidal, dimeric and polymeric
forms. Indeed, taken in consideration the complexity of the
technetium chemistry, it is easy to understand that the trans-
lation of the results obtained at carrier level (Tc-99) to the
chemistry at no-carrier level (Tc-99m), is not a straightfor-
ward procedure and represents a challenge to investigation.
Attempts to characterize Tc-99 bisphosphonates complexes
by gel chromatography, HPLC, amperometric titrations, po-
larography, etc., reveal a mixture of several complexes,
which are produced in relative amounts and yields depend-
ing mainly on the pH and oxygen content (7 and references
wherein). Reversed-phase HPLC of Tc-99m bisphospho-
nates have shown also complicated mixtures of several
radiochemical species [23]. Libson et. al. [20] have isolated
a Tc-99-MDP polymeric complex with an approximate oc-
tahedral coordination. Each MDP ligand bridges two sym-
metry Tc atoms, and each Tc atom is bound to two sym-
metry MDP ligands. Similar problems would occur with
rhenium, whose chemistry is closed related to technetium,
and there is not any available information on rhenium co-
ordination complexes with bisphosphonates. On the other
hand, a series of lanthanides complexes with HEDP (1-
hydroxyethane-1,1-diphosphonic acid) were studied by
Nash K. L. et al. [26]. Three different structural variations
of the 1:2 complexes have been observed:
Y Nd crystallizes as a heptahydrate with an eight-coor-
dinate square antiprismatic structure, [Nd (H3 HEDP)
(H2 HEDP)].7H2O, the metal ion being coordinated in
a linear polymeric fashion to four HEDP ligands via
PO, P-O- and one P-OH moiety,
Y Eu complex [H3O] [Eu (H2HEDP)2].12H2O, is also
an eight-coordinate polymeric structure and has the
highest symmetry of any of the complexes character-
ized,
Y the heavy lanthanides (MTb, Dy, Ho, Er, Tm, Yb,
Lu, Y) form an isostructural series of compounds in a
seven-coordinate capped trigonal prismatic geometry
[M((H3 HEDP) (H2 HEDP)].5H2O. The overall coor-
dination to four HEDP ligands in a linear polymer, is
comparable to that for the Nd and Eu complexes,
except that the seven-coordinate metal ions release
one P-O site which coordinates the fifth hydrogen ion.
The extensive intramolecular hydrogen bonded network
and water molecules sequestration is consistent with the
previous observation of low complexation entropy and exo-
thermic heats, for europium BPs complexes [25].
1.3. Calcium affinity by metal-bisphosphonates complexes
The chemistry of bone imaging agents ultimately resides
in the high calcium affinity of the bisphosphonates even
after they are coordinated to a metal. To a first approxima-
tion, it is the bisphosphonate ligand, and not the nature of
the bisphosphonate-metal complex, that determines the bio-
distribution. This is evidenced by the fact that HEDP la-
beled with P-32, HEDP complexed to Sn-113, HEDP com-
plexed to Re-186 and HEDP-Tc-99m complexes prepared
by reduction of pertechnetate with Sn(II), NaBH4 and Cu(I),
all accumulate in bone. Thus, the HEDP-metal complexes
bone uptake is not dependent on the nature of metal center,
but is primarily driven by the nature of the ligand (7 and
references herein). In fact, the HEDP-metal complexes
(MSn, Re, Tc, Cu) have not exactly all the same bone
uptake, but deviations could be explained by the different
complexes involved, which have distinct chemical and
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physical natures. According to Jurisson et al. [15] the ap-
parent equilibrium constants, governing the association of
calcium (II) with several coordinated bisphosphonate li-
gands are large, ranging from 4  103 to 2  106 M-1,
showing that even after coordination the bisphosphonate
ligand has considerable affinity for calcium. The calcium
affinity of ligands as (O3P-C(R)(R)-PO34-) depends
strongly on the nature of the R and R groups, the observed
variations result from steric, electronic and chelate effects.
Binding to calcium of a coordinated bisphosphonate can
occur not only through the common PO3 groups but also
through to the specific R groups. This additional binding
mode converts the bisphosphonate ligand from a bidentate
to a tridentate bridge, which it is expected to enhance the
calcium affinity of the coordinated bisphosphonate. Some
authors [13], claim that in vitro studies of 99mTc-BPs com-
plexes adsorption on calcium phosphate are important as a
pre-evaluation of bone uptake. It was also possible to es-
tablish a rationale correlation between adsorption properties
of radioactive metal BPs complexes and the structures of the
free ligands, as MDP, HMDP and HEDP labeled with C-14
[10].
2. Molecular modeling
Computer-assisted molecular design has become a key
component on the elucidation of the relationship between
molecular structure and function of biological systems.
Computer modeling allows the generation and evaluation of
physicochemical properties of molecular systems and, by
simulation of intermolecular interactions, can be used to
recognize potential sites and lead to the understanding of
biological phenomena. Molecular recognition at the inter-
face between inorganic materials and organic templates is
known to be a powerful force in the control of crystalization
and mineralization in both synthetic and biologic systems.
For example, the interaction between alkyldiphosphonates
and the surfaces of barium sulfate was studied at molecular
level using molecular modeling techniques, in order to es-
tablish a reliable mechanism for crystal growth inhibition by
molecules [2]. The relative effectiveness of phosphonate
retarders on hydrating cements was also evaluated by com-
putational methods through the simulation of specific inter-
actions between several phosphonates and a surface layer of
ettringite [6]. In the present study, the interactions between
three BPs differing only in the length of their aliphatic
chain: (pamidronate  (CH2)2  NH2; alendronate 
(CH2)3  NH2; neridronate  (CH2)5  NH2) and an
infinite periodic surface of hydroxyapatite, were evaluated
by molecular modeling using the second generation CVFF
950 (version 1.01) force field.
Prior to simulate the interactions of the BPs with hy-
droxyapatite, a detailed study of the preferred conforma-
tions (a three-dimensional arrangement of atoms) assumed
by the isolated molecules of the studied BPs was under-
taken. This study provided the necessary basic knowledge
on the molecular structure of the BPs, thus enabling the
further later identification of the main structural changes
suffered by the BPs due to the interaction with hydroxyap-
atite. Among the various available methods to compute
molecular structures, molecular mechanics (MM) is able to
predict structures with high accuracy and little computa-
tional expense, even for large molecular systems [4]. Basi-
cally, MM assumes that the energy (E) of a given molecule
can be described as a sum of energies associated with
distortions of its different internal mechanical degrees of
freedom (bond stretchings, E, angle bendings, E, torsions,
E, changes in non-bonded distances Enb) from their “nat-
ural geometry” and specific electrostatic (Coulomb type,
EC) interactions (additional terms can be added to consider
specific interactions, like, for instance, hydrogen-bonding):
E  E  E  E  Enb  EC  . . .
E is sometimes named “steric energy” [27], and it represents
the difference between the energies of the real molecule and
the hypothetical molecule where all the structural parame-
ters assume their “natural values”. The whole set of func-
tions used to describe the different energy contributions is
named “force field” and this is strongly dependent on both
the analytical form of the potential energy function used to
represent a given type of contribution and the particular set
of parameters defining each particular interaction of a given
type (e.g., C-C or C-O stretching; C-O-C or C-C-C bending,
C-C or C-N torsion, etc.). Experience has shown that the
choice of functions in the force field is critical. In addition,
while a variety of efficient and fast computational algo-
rithms are widely available, the final force field should be
both reliable and simple. In the present study, the second-
generation CVFF 950 (version 1.01) force field of Hwang
and co-workers [14] was selected for calculations. These
were made using the Cerius-2 system of programs [5] run-
ning in a Silicon Graphics O2 workstation.
3. Material and methods
3.1. General
The ligands pamidronate, alendronate and neridronate
are prepared according to the general procedure to linear
aliphatic BPs [18] and characterized by elemental analysis,
1H-NMR and 13C-NMR. 153Sm was produced in the Por-
tuguese Nuclear Reactor at a neutron flux of 2  1013
n.cm-2.s-1 from samarium oxide enriched targets 98%
(Campro Scientific). Hydroxyapatite Bio-Gel® HTP Gel is a
Bio-Rad Laboratories product. Unless otherwise indicated
all materials used were reagent grade.
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3.2. Ligand synthesis
The ligands pamidronate, alendronate and neridronate
(n  2, 3, 5), were prepared from the corresponding car-
boxylic acid percursors according to the following reaction:
Alendronate monosodium trihydrate—(C4H12N NaO7P2.3H2O):
To aminobutanoic acid (2 g, 1.9  10-2 mol) in a
three-necked round-bottom flask H3PO3 (1.6 g, 1.9 
10-2 mol) was added under inert atmosphere followed by
8 mL of methanesulfonic acid. After heating at 65°C,
PCl3 (3.5 mL, 4  10-2 mol) was added and the reaction
allowed to proceed for 20 –22 hours. The resulting yellow
viscous reaction mixture was cooled to room temperature
and quenched with 30 mL of ice-cold water. The pH was
adjusted to 4.3 with NaOH solution and the white pre-
cipitate formed was collected by filtration, and then air
and vacuum dried at 40°C, to give alendronate monoso-
dium trihydrate (4.39 g, 70%), as white crystals, m.p.
270 –274°C; 1H NMR (D2O):  2.97 (2H, t), 1.93 (4H, t),
13C NMR (D2O):  39.97, 30.56, 22.10 (); Elemental
Analysis for C4H12NNaO7P2.3H2O, % Calculated: C
14.78, H 5.58, N 4.31; Found: C 14.70, H 5.63, N 4.11.
Pamidronate and neridronate were prepared in a similar
manner following the procedure above described for
alendronate by using -alanine and 6-aminocaproic acid
respectively as starting materials. Physical and spectral
data obtained were as follows:
Pamidronate monosodium monohydrate—(C3H10N
NaO7P2.0.5H2O): as a white solid (5.48 g, 35%): 1H
NMR (D2O):  3.32 (2H, t, J  6.9 Hz), 2.27 (2H, m);
13C NMR (D2O):  73.66 (t, JC-Pn  132 Hz), 37.06,
31.50 (t); Elemental Analysis for C3H10NNaO7P2.H2O,
% Calculated: C 13.10, H 4.40, N 5.09; Found: C 12.85,
H 4.34, N 4.83.
Neridronate monosodium monohydrate—(C6H16N
NaO7P2.0.5H2O): as a white solid (3.99 g, 42%): m.p.
263–266°C, 1H NMR (D2O):  3.05 (2H, t, J  7.6 Hz),
1.90–2.05 (2H, m), 1.61–1.79 (4H, m), 1.44 (2H, m); 13C
NMR (D2O):  74.92 (t, JC-Pn  132 Hz), 40.06, 36.00,
26.81, 26.66, 26.36 (t, JC-Pn  6.8 Hz); Elemental Analysis
for C6H16NNaO7P2.0.5 H2O, % Calculated: C 23.39, H
5.56, N 4.55; Found: C 22.90 H 5.65 N 4.39.
3.3. Synthesis and characterization of 153Sm-BPs complexes
The reactions were conducted according to the procedure
described by Zeevaart et al. [33] for 166Ho-pamidronate. To
each ligand in alkaline solution, was added the required
amount of the radioactive solution in chloride form
(153SmCl3), according to a ligand/metal molar ratio ranging
from 110 to 170, and the pH ajusted to 8–9. Complexation
of the radioactive metal, was assessed by ascending chro-
matography, using ITLC-SG (Gelman Sciences Inc., Ann
Arbor, MI) strips developed with H2O/NH4OH (25:1) (A
system) and acetone/H2O/HCl (7:2:1) (B system).The pro-
files of the peaks were drawn using a Bioscan AR-2000
scanning equipped with a scintillation probe.
3.4. Hydroxyapatite binding
To vials containing 5.0, 10.0, 15.0, 20.0, 25.0 and 50.0
mg of hydroxyapatite, were added 2 mL of physiological
saline solution at pH  7.4 and the mixtures shaken for 24
hours at 37°C into a water-bath. Then, 50 L of each
radioactive preparation was added and the mixtures shaken
for 24 hours at 37°C. All suspensions were filtered through
a 0.2 m Millipore filter, centrifugated and two aliquots of
100 L were taken from each vial and the radioactivity
measured into a DPC Gamma-C12 counter, calibrated for
153Sm. Blanks were also prepared in the same experimental
conditions, except the presence of hydroxyapatite. Six vials
were assayed for each preparation. The percentage binding
to hydroxyapatite (HB) was calculated by HB  (1 
A/B)  100, being A the mean value of the measured
radioactivity of samples under study and B the mean value
of blanks.
3.5. Animal studies
The animal experimentation was performed in accor-
dance with the National Code for the Handling and Use of
Animals in Research, Education, Diagnosis and Testing of
Drugs and Related Substances (which conforms to the in-
ternationally accepted standards). Quantitative tissue distri-
butions of the 153Sm–BPs complexes were evaluated in
groups of six female mice (randomly-bred Charles-River,
Wilmington, MA), weighting approximately 25 grams each.
Animals were intravenously injected with 100L (5–10
MBq) of each radioactive preparation via the tail vein and
were maintained on a normal diet ad libitum. The injected
dose was measured using a calibrator. At 1, 3 and 24 hours
after injection the animals were sacrificed by cervical dis-
location, and weighted. Femurs were removed, weighted
and assayed by gamma counter (DPC Gamma-C12). Skel-
etal uptake was determined assuming that bone represents
10% of all body weight. Thus, radioactivity in all bone was
calculated from the femur radioactivity uptake. The results
are expressed as percent of injected dose (% ID).
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4. Results and discussion
4.1. Molecular modeling
In order to test the performance of the selected force
field, we started the calculations by modeling the structure
of alendronate and comparing the resulting geometry with
that obtained experimentally [32]. Even though the proper-
ties being compared are not exactly equivalent (experimen-
tal structure refers to the crystalline state, whereas the cal-
culated structure corresponds to the isolated molecule
equilibrium geometry), the theoretical and experimental
data show a fairly good agreement. Since the calculations
were able to reproduce satisfactorily the experimental ge-
ometry for alendronate, it was assumed that the structures of
pamidronate and neridronate could also be estimated rea-
sonably (Fig. 1). The different conformational states of the
three BPs studied were obtained by multiple minimization
of randomly generated initial structures. The number of
initial structures generated was 1000 with all torsional an-
gles let free to vary in the optimization procedure. For
pamidronate, 10 different conformers with energies within 5
kcal mol-1 relatively to the global minimum were obtained
as a result of this process, while for alendronate and neridr-
onate the calculations predict, respectively, 34 and 171
different conformers within this range of energies (Fig. 2).
The large increase in the number of conformers with the
length of the carbon chain could be anticipated, since the
conformational flexibility must increase with the number of
torsional degrees of freedom in the molecule. For the three
molecules, the density of states was found to increase sig-
nificantly with the energy. Indeed, the energy difference
between the first excited and the ground conformational
states in pamidronate is 	E*(1–10) 
 1.5 kcal mol-1, while
the next 8 excited conformational states have energies dif-
fering only by ca. 1.8 kcal mol-1 (	E*(10–2)). For alendro-
nate, 	E*(1–0) 
 0.9 kcal mol-1, 	E*(10–2) 
 1.2 kcal mol-1
and 	E*(34–11) 
 1.8 kcal mol-1, while for neridronate
	E*(1–0) 
 0.3 kcal mol-1, 	E*(10–2) 
 0.7 kcal mol-1,
	E*(34–11) 
 0.7 kcal mol-1 and 	E*(171–35) 
 2.8 kcal
mol-1 (see also Fig. 2). It can then be concluded that for the
isolated BPs, the most stable conformer assumes a particular
importance from a practical point of view, thus justifying a
more detailed analysis of its structure.
For both pamidronate and alendronate, the most stable
conformer is characterized by the presence of an intramo-
lecular OH . . . N hydrogen bond. The establishment of this
bond leads to stabilization of gauche conformations of the
carbon chain, in order to ensure the most favorable hydro-
gen bond interaction geometry. In the case of neridronate,
the global minimum was found to correspond to a con-
former that shows an all-trans (zig-zag) carbon chain. This
different conformational behavior can be easily understood
taking into consideration that hydrocarbon chains assume
preferentially this type of conformation unless other in-
tramolecular interactions can compensate the increase of
energy due to the presence of gauche conformations around
the C-C bonds. So, while in the case of pamidronate and
alendronate, the presence of the intramolecular hydrogen
bond can compensate energetically the destabilization due
to the gauche arrangements necessary to obtain the most
favorable hydrogen bond interaction geometry, in the case
of neridronate, the stabilization due to the intramolecular
hydrogen bonding is not enough to compensate the increase
of energy associated with the gauche arrangements.
Once the main structural trends in the BPs were estab-
lished, the intermolecular interactions between these mole-
cules and hydroxyapatite could be examined. To do this, the
molecule of each BP was placed in the vicinity of the (001)
Miller plane of the crystal of hydroxyapatite, which has
been described previously as the most favorable growing
Fig. 1. Molecular geometries of the most stable conformers of pamidronate (A), alendronate (B) and neridronate (C) (isolated molecule in vacuum).
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surface of hydroxyapatite [1]. The crystalline structure of
hydroxyapatite reported by Kay and Young [16] was used in
the simulations. Hydroxyapatite crystal is constituted by
layers of phosphate and hydroxide groups intercalated with
layers of calcium ions. The (001) surface of the hydroxy-
apatite crystal, shows that each hydroxyl group is sur-
rounded by six calcium atoms, three in one plane and the
remaining three in an adjacent plane (Fig. 3).
In order to obtain the minimum energy BP-hydroxyapa-
tite complex, a systematic search on the potential energy
surface of the BP-hydroxyapatite (001) surface complex
was performed. The structure of hydroxyapatite was con-
sidered fixed during the energy minimization process while
geometries of the BPs were fully optimized. For each BP,
from the whole set of complexes obtained by this way, the
lowest energy species was selected for further analysis. The
minimum energy hydroxyapatite complexes of the three
BPs studied are shown in Fig. 4.
From the results presented in Fig. 4, the following main
conclusions could be drawn:
Fig. 2. Conformational energy levels (kcal mol-1), relative to the conformational ground state for pamidronate (A), alendronate (B) and neridronate (B).
Fig. 3. Three-dimensional and top view of hydroxyapatite:  ca atoms;  phosphate groups.
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(i) The most important intermolecular interactions oc-
cur between the phosphate and amino groups of BPs
and the calcium ions of hydroxyapatite. Since both
the oxygen atoms of the phosphate groups and the
amino nitrogen atom (bearing one electron pair)
shall have relatively large partial negative charges
and the calcium atoms are positively charged, it can
be expected that the dominant intermolecular inter-
actions in the complexes are electrostatic in nature.
The strength of these interactions is then strongly
dependent upon the distance between the interacting
charges, decreasing with the inverse of the square of
the distance. Considering that the three BPs under
study only differ in the length of their aliphatic chain
bearing the amino group, it can be stated that, con-
trarily to the phosphate-calcium interactions (which
shall not differ appreciably in the different complex-
es), the interaction between the amino group and the
calcium ions of the matrix are unique for each
bisphosphonate. The calculated distances between
the nitrogen atoms and the nearest calcium atoms are
5.77 Å for pamidronate, 3.75 Å for alendronate, and
5.07 Å for neridronate, implying stabilizing interac-
tion energies that are similar for pamidronate and
neridronate, but significantly more important for
alendronate. The anti-resorption potencies relative to
etidronate measured in vivo (in rats) were found to
be 100, for both pamidronate and neridronate, and
in between 100 and 1000 for alendronate [8].
Indeed, the pharmacologic activity of alendronate
has been proved to be higher than those of pamidr-
onate and neridronate, and alendronate has become
established as a drug for treatment postmenopausal
and other forms of osteoporosis [19,30]. Hence, the
experimentally observed anti-resorption potencies
exhibited by the three BPs studied correlate well
with the calculated values for the corresponding
amino-calcium interaction energy, indicating that
this interaction may play a relevant role in determin-
ing the relative ability of BPs to act as anti-resorp-
tion agents.
(ii) The optimized structures of the BPs within the com-
plex were found to be significantly different from
those corresponding to the ground state conformer
for the isolated BPs. In particular, in both the cases
of pamidronate and alendronate, the intramolecular
OH . . . N hydrogen bond which characterizes the
most stable conformer of the isolated molecules does
not remain in the surface-bound species, since the
amino group is, as discussed, involved in the coor-
dination with calcium. The energy difference be-
tween the conformation assumed by alendronate on
the surface and that of the most stable conformer of
the isolated molecule was calculated to be smaller
than those obtained for the remaining two BPs. So,
these results follow the same trend discussed in i)
and is a further indication that alendronate has a
structure that enables a better fit to the hydroxyapa-
tite crystal preferred binding sites.
4.2. Radiochemistry
Radioactive preparations with radiochemical purity
higher than 97%, were identified as described. The 153Sm-
BPs complexes evaluated by the A system, migrate (Rf 
0.8–1.0), while ionic 153Sm and colloidal radioactive forms
remains at the origin. The 153Sm-BPs complexes and the
ionic 153Sm evaluated by the B system, migrate (Rf 
0.8–1.0), while colloidal radioactive forms remains at the
origin. With these two systems it is possible to identify the
three expected main radiochemical components: 153Sm-BPs
complexes, ionic 153Sm and radioactive colloidal forms
Fig. 4. Spatial view of the minimum energy complexes of pamidronate (A), alendronate (B) and neridronate (C) on the (0, 0, 1) surface of hydroxyapatite.
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which could be considered as a mixture of hydroxy-des
and/or neutral 153Sm complexes.
4.3. Hydroxyapatite binding
The hydroxyapatite binding expressed as the percentage
adsorption of 153Sm-pamidronate, 153Sm-alendronate and
153Sm-neridronate function of the amount of hydroxyapa-
tite, is shown in Fig. 5. The adsorption curves have a similar
profile as the described for 99mTc-bisphosphonates adsorp-
tion curves on tri-calciumphosphate [13]. The maximum
percentage adsorption values, higher than 95%, were
achieved by 153Sm-alendronate and 153Sm-neridronate us-
ing amounts of hydroxyapatite higher then 25 mg, but the
highest percentage adsorption for the minimum amount of




Skeletal uptake for 153Sm-pamidronate, 153Sm-alendro-
nate and 153Sm-neridronate expressed in % ID is shown in
Fig. 6. The highest value of skeletal uptake, was achieved at
3 hours after injection by 153Sm-neridronate (19.9%), but at
24 hours the highest skeletal uptake value was observed for
153Sm-alendronate (9.2%).
5. Conclusion
Molecular modeling studies on the isolated BPs, pam-
idronate, alendronate and neridronate, and on their hydroxy-
apatite complexes were undertaken. The molecular confor-
mations adopted by the three BPs on the (001) surface of the
hydroxyapatite crystal are markedly different from those
corresponding to the isolated BPs, the most important struc-
tural changes being due to the need to satisfy the steric
requirements for more favorable intermolecular interac-
tions.
A good correlation could be established, between the
experimentally available in vitro and in vivo experiments of
the three 153Sm-BPs complexes and the corresponding in-
teraction energies resulting from the Coulombic interaction,
involving the nitrogen atom of the BPs and the nearest
calcium atom of hydroxyapatite in the most stable BP-
hydroxyapatite complexes. In fact, the results of experimen-
tal hydroxyapatite binding and skeletal uptake of 153Sm-BPs
complexes indicate that 153Sm-alendronate is preferred
comparatively to 153Sm-pamidronate and 153Sm-neridr-
onate. This is in agreement with the calculated BPs-calcium
interaction energy that was shown by the molecular mod-
eling studies to be significantly larger for alendronate than
for the remaining BPs, as revealed by the shorter distance
between the amino group and the nearest hydroxyapatite
calcium atom observed in the alendronate-hydroxyapatite
complex. These results seem to indicate that specific inter-
actions involving the chain groups of the different BPs may
play a relevant role in determining their relative ability to
act as anti-resorption agents. On the other hand, they also
point to the fact that the nature of the bisphosphonate-metal
complexes do not play a decisive role in hydroxyapatite
binding and skeletal uptake, confirming what was previous
observed by others authors [7,10,15]. These conclusions are
very important for the design of new BPs as drugs for bone
diseases and as ligands to carrier radioactive metals. Also,
from this work, it is also possible to conclude that molecular
modeling studies are a good approach to evaluate specific
interactions between BPs and hydroxyapatite and then it
appears as a suitable method to be used in the design of new
BPs with increased pharmacologic activity, and in the de-
sign of new bone therapeutic radiopharmaceuticals before in
vitro and in vivo studies.
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